نتائج البحث - John Reader

  • يعرض 1 - 6 نتائج من 6
تنقيح النتائج
  1. 1
    Complex synthetic chemical libraries indexed with molecular tags.

    Complex synthetic chemical libraries indexed with molecular tags. حسب Michael Ohlmeyer, R. N. Swanson, Lawrence W. Dillard, John Reader, G Asouline, Ryouji KOBAYASHI, Michael Wigler, W. Clark Still

    منشور في 1993
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Inhibition of TYK2 and JAK1 Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis by Inhibiting IL-22 and the IL-23/IL-17 Axis

    Inhibition of TYK2 and JAK1 Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis by Inhibiting IL-22 and the IL-23/IL-17 Axis حسب Melissa Works, F Yin, Catherine Yin, Ying Ying Yiu, Kenneth Shew, Thanh-Thuy Tran, Nahoko Dunlap, Jennifer S. Lam, Timothy J. Mitchell, John Reader, Paula Stein, Annalisa D’Andrea

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

    The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106 حسب Michael I. Walton, Paul D. Eve, Angela Hayes, Melanie Valenti, Alexis de Haven Brandon, Gary Box, Kathy Boxall, G. Wynne Aherne, Suzanne A. Eccles, Florence I. Raynaud, D. H. Williams, John Reader, Ian Collins, Michelle D. Garrett

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

    CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs حسب Mike I. Walton, Paul D. Eve, Angela Hayes, Melanie Valenti, Alexis K. de Haven Brandon, Gary Box, Albert Hallsworth, Elizabeth Smith, Kathy Boxall, Michael Lainchbury, Thomas P. Matthews, Yann Jamin, Simon P. Robinson, G. Wynne Aherne, John Reader, Louis Chesler, Florence I. Raynaud, Suzanne A. Eccles, Ian Collins, Michelle D. Garrett

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

    The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma حسب Mike I. Walton, Paul D. Eve, Angela Hayes, Alan T. Henley, Melanie Valenti, Alexis K. de Haven Brandon, Gary Box, Kathy Boxall, Matthew Tall, Karen E. Swales, Thomas P. Matthews, Tatiana McHardy, Michael Lainchbury, James Osborne, Jill V. Hunter, Neil D. Perkins, G. Wynne Aherne, John Reader, Florence I. Raynaud, Suzanne A. Eccles, Ian Collins, Michelle D. Garrett

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing

    Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing حسب John Reader, Thomas P. Matthews, Suki Klair, Kwai-Ming J. Cheung, Jane Scanlon, Nicolas Proisy, Glynn Addison, John Ellard, Nelly Piton, Suzanne Taylor, Michael Cherry, Martin Fisher, Kathy Boxall, Samantha Burns, Michael I. Walton, Isaac M. Westwood, Angela Hayes, Paul D. Eve, Melanie Valenti, Alexis de Haven Brandon, Gary Box, Rob L. M. van Montfort, D. H. Williams, G. Wynne Aherne, Florence I. Raynaud, Suzanne A. Eccles, Michelle D. Garrett, Ian Collins

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: